{"name":"Enanta Pharmaceuticals","slug":"enanta","ticker":"ENTA","exchange":"NASDAQ","domain":"enanta.com","description":"Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered i","hq":"Watertown, MA","founded":0,"employees":"120","ceo":"Jay R. Luly","sector":"Liver Disease / Antivirals","stockPrice":13.96,"stockChange":-0.07,"stockChangePercent":-0.5,"marketCap":"$406M","metrics":{"revenue":102814000,"revenueGrowth":15,"grossMargin":100,"rdSpend":106740000,"netIncome":-81889000,"cash":163774000,"dividendYield":0,"peRatio":-6.8,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Mavyret patent cliff ($1.4B at risk)","drug":"Mavyret","type":"patent_expiry","sentiment":"negative"},{"date":"2029-06-01","label":"Viekira Pak patent cliff ($1.1B at risk)","drug":"Viekira Pak","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"EDP-235","genericName":"EDP-235","slug":"edp-235","indication":"Other","status":"phase_2"},{"name":"EDP-323 Dose Regimen 2","genericName":"EDP-323 Dose Regimen 2","slug":"edp-323-dose-regimen-2","indication":"Other","status":"phase_2"},{"name":"EDP-323 Dose Regimen 1","genericName":"EDP-323 Dose Regimen 1","slug":"edp-323-dose-regimen-1","indication":"Other","status":"phase_2"},{"name":"EDP-494","genericName":"EDP-494","slug":"edp-494","indication":"Other","status":"phase_1"},{"name":"intraconazole","genericName":"intraconazole","slug":"intraconazole","indication":"Other","status":"phase_1"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Carbamazepin","genericName":"Carbamazepin","slug":"carbamazepin","indication":"Bipolar affective disorder, current episode manic","status":"marketed"}]}],"pipeline":[{"name":"Carbamazepin","genericName":"Carbamazepin","slug":"carbamazepin","phase":"marketed","mechanism":"Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4","indications":["Bipolar affective disorder, current episode manic","Bipolar disorder in remission","Epilepsy","Epilepsy characterized by intractable complex partial seizures","Glossopharyngeal neuralgia"],"catalyst":""},{"name":"EDP-235","genericName":"EDP-235","slug":"edp-235","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"EDP-323 Dose Regimen 2","genericName":"EDP-323 Dose Regimen 2","slug":"edp-323-dose-regimen-2","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"EDP-323 Dose Regimen 1","genericName":"EDP-323 Dose Regimen 1","slug":"edp-323-dose-regimen-1","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"EDP-494","genericName":"EDP-494","slug":"edp-494","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"intraconazole","genericName":"intraconazole","slug":"intraconazole","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Enanta Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Enanta Pharmaceuticals reported its fourth quarter and full year 2023 financial results, with revenue of $143.8 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-12-06","type":"deal","headline":"Enanta Pharmaceuticals Announces Collaboration with AbbVie to Develop New Hepatitis C Treatments","summary":"Enanta Pharmaceuticals announced a collaboration with AbbVie to develop new hepatitis C treatments.","drugName":"","sentiment":"positive"},{"date":"2023-08-04","type":"regulatory","headline":"FDA Approves AbbVie's Mavyret for Treatment of Chronic Hepatitis C","summary":"The FDA approved AbbVie's Mavyret (glecaprevir/pibrentasvir) for the treatment of chronic hepatitis C.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOaWdERFVwVXNuOXIzMG9ETFZWZ3RYWHpMVkhZSHFUMlhqbGg2UWJCeWZIby1RYjhKY0dSeGpBMTZIU1NWZ0tGSnlYejhHeTNWS1VXYkJ2UDA1dTJvRFRORzNUNDFHYnZ0cERFeUg5Ty1QZFVZYnlKa0hXSlZmMHo5cVpKNzhtaVluekxaQ0tXRG5Nc1Z6NXJaZ1owMzF6VUl0WVdqa25NejBqai15eHR6YTZ4YWpJUVNsUloyNkNn?oc=5","date":"2026-01-07","type":"pipeline","source":"AD HOC NEWS","summary":"Enanta Pharmaceuticals Is Exploding On Watchlists – But Is ENTA Stock Actually Worth Your Money? - AD HOC NEWS","headline":"Enanta Pharmaceuticals Is Exploding On Watchlists – But Is ENTA Stock Actually Worth Your Money?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNWE9KaUQ0TmJiLXd5ZElRMFBlLWZGRGYzSDNpRS1oTDA4TE1XVkM2b3dBMnBadWtYLTJ4eTI4d3dOYWk3aDVwbExHMWxNVWx2Z01VV3NxYnY0ZFpfcV90Zk5NWnBnNVBSOGN1Wld3LWY0bElTTXlteVJ0Ti1qb0poaVNON1U?oc=5","date":"2025-11-14","type":"pipeline","source":"Seeking Alpha","summary":"Enanta rises as J.P. Morgan starts at Overweight on RSV therapy - Seeking Alpha","headline":"Enanta rises as J.P. Morgan starts at Overweight on RSV therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxOZFB2Y3lnOFY0dDNsYlBINzNFRmNFY2llWTRaNDhoQmw2b09rT25POXp2SFEtQ2piMExSVU53UUFWYjFxUE9uNm4zS1U0RzBXd01JYWNTUW1IYzU5dnF2cWlSTlZUMHBFVUVoUGdycW5vZjhOVVh5N2ZQaFQwdXRDRWRqQlNEZEtqeXdnM1NPb05sODY2N1Nuc1hlczQ5c0FnRTVRTmFkallUYzRnbGZoaTFUUEVUY1h3dEFzd1M1dWhTQkphTVVqck5R?oc=5","date":"2025-09-30","type":"pipeline","source":"Business Wire","summary":"Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock - Business Wire","headline":"Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxOS3E2S1ozbW84enJWbmRVY1JDZzhZdWctZXRmTFdRQ1ZnTXcxeVVGUUJDWlo4NlpFblNTR0FtTUJCRUxreGxSaVN2MnAzNkRDejdRUDR6VWh2WXVLQWo3TDFNLVFmMG9uNklHX2FjLUc3cWVmS3dFYzhqWDBJZVZ1VnlPMWlma29iM0IwVjVaeTk4OFNOM1dkc0kxU2lmV2p4MnRwMi0yT3N1TFNfd2RuZ08tOERZeGNOR2x0T1NKTFEyWXlmRXc0a20wQUs5RHhzVkRxM1NxbTZ4eDFIT3BzbzV0YzM4aGdNcGc?oc=5","date":"2025-09-29","type":"pipeline","source":"Stocktwits","summary":"Enanta Pharmaceuticals Stock Rises 58% – Here’s An Important Update - Stocktwits","headline":"Enanta Pharmaceuticals Stock Rises 58% – Here’s An Important Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNTl8tUEI1Y200dFlTeVpubHAwZTFQNFlicC1CSzZRcmRBV2t4MkRhWmFxSm1fa2U2SDFlcmczZFFzc1lrTVhKcnRCbHc2OElROUFvcGc4MWVXZWZEeUtXeWw0RTlsNlRRRXhyV0h4clo4ZDcyYUp2ejViM0Zrc2RSWEJScUx3WjN2dGxrdGYwR1Z5SVUxQ3hpQVd1OWQtOG84YUdwVmMxeHpiRjFZZk9tRmxRZmE?oc=5","date":"2025-09-29","type":"trial","source":"Seeking Alpha","summary":"Enanta: Despite Primary Endpoint Miss Zelicapavir Could Benefit From Trial Design Change - Seeking Alpha","headline":"Enanta: Despite Primary Endpoint Miss Zelicapavir Could Benefit From Trial Design Change","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQSThMOGZGa29jbHliU2pzdDBIYk5mNjRvVGs1TDRUMDF6NWRFeW51ZHZ5SFpac29ldXhCTTRTcks0eHJEMjRGeVcxREZZa3ZHb2VaM0hNd1d0SjdldEtaRHM4c0E5TThoZEFGZVo1UDFld2M3Q1RKUFZtcUFNU0tFcnhyRlV4V0NseEctUDk3ZmRmSm05NmVXdzhYQUhZUVV3aEVtWDItVE13eDVFa2ZjV0daTFBhODdTeE12d09DSmU5N2hOenNZ?oc=5","date":"2025-08-20","type":"patent","source":"MSN","summary":"Pfizer sued by Enanta in EU over patent infringement related to COVID pill - MSN","headline":"Pfizer sued by Enanta in EU over patent infringement related to COVID pill","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxPMGZkT1NDQ1FaUlM4TXdhaE13UlA4STZBRUFiQ29sQkg5NmpYRkpjWmhKNEdOel9fdFdhODZXcEZYNWIwZ3pSaEE2aWluOTBlV25mYmVjdU5JLTNsZTJLeEI0QzB2ZWpTNXlrZzJMYnZCS01hVjRadGNQN0hCTHh2N1lqRGg1SmVzZTMzcWZwWldWU2loVDI2UkhtSXdwUHI2YmxnQzdISlZWZWRfZXBBd3hIZ2JKOEFuRnk4RUlPcW9tVm5YLXBDRXFhUGY5ekQtUXEwWXRkUkI4ckZ4YzJuYnFuTE1BVXpD?oc=5","date":"2025-08-11","type":"earnings","source":"Business Wire","summary":"Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025 - Business Wire","headline":"Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1TTzlKWUwtMFVJVEpaUGJ3YmdLSkNDNHZ6ZEh2S042QVVpVnQ2ZDhKOFFoakdDYkpWT2JtWFhKaEltV1ctc0ZLc3dwWE1oRE5uSmtj?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"ENTA Stock Price, News & Analysis | Enanta Pharmaceuticals - Stock Titan","headline":"ENTA Stock Price, News & Analysis | Enanta Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxPV2ZhV2hSSkZIYlpWQ1dKOXpDR3hYQlB1N1FwekJycFU4cWtQZjhraTN3ZmhBcUlablVYZnJXcHVKUnd0UTlJRlI5RVFOV2UtdWtrcmxiRm9HNVRyd3FEZllpYVdPY1dYTS1VaDhORFlOWWFfYWZGX0JrTHhKbXVzeGRFZnBaM0hqM0g3UGZGRkUza0NmaFRHckVIbHpCeWVUV3ZleVItTnFhMzV4MVR4cUk1NjdsZksyVnZ3MFNEQkM3c2p3ZnE5S1p2TERvcnRYbFo1TWdhbmhCVXQzWlU5Rkk1dXoyZ0VFd1lvV0N4Yw?oc=5","date":"2020-12-08","type":"pipeline","source":"BioSpace","summary":"Enanta Pharmaceuticals Announces the Appointment of Tara L. Kieffer, Ph.D. as Senior Vice President, New Product Strategy and Development - BioSpace","headline":"Enanta Pharmaceuticals Announces the Appointment of Tara L. Kieffer, Ph.D. as Senior Vice President, New Product Strateg","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiSEFVX3lxTE9uLW9CNV8xUEItUmR0N2drdXc1dUNlUVJtY2FzSW52NDVSaWZ2NFJLS1A0YTlKdDNhNGdnbkRfNVRVdjBiaWVRcg?oc=5","date":"2020-12-01","type":"deal","source":"StockInvest.us","summary":"Enanta Pharmaceuticals Stock Price Forecast. Should You Buy ENTA? - StockInvest.us","headline":"Enanta Pharmaceuticals Stock Price Forecast. Should You Buy ENTA?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE42N3Y2NE9HVHBpOXc5T2dZRlA1XzF4ZXBFcVpscGJEQkVLWHB4Z2E5VW14YnFEOThEZlFJNWc5T0VOQ0NCbDYxdW1hbjVmY09MbmRpSThTLXpFZEJt?oc=5","date":"2017-07-23","type":"pipeline","source":"TradingView","summary":"ENTA Stock Price and Chart — NASDAQ:ENTA - TradingView","headline":"ENTA Stock Price and Chart — NASDAQ:ENTA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE1QakI0Um1pam1VcU5Od2VEeEpJSm12WktkMms0dS1wZjRWSkJPTnhOWE5NWVhxT01RYUE3aGx3V0V3Qk5TeEZDQTFlcG50SE1zVWxxMXZMVjQzUQ?oc=5","date":"2016-08-11","type":"pipeline","source":"MarketBeat","summary":"Enanta Pharmaceuticals (ENTA) Stock Price, News & Analysis - MarketBeat","headline":"Enanta Pharmaceuticals (ENTA) Stock Price, News & Analysis","sentiment":"neutral"}],"patents":[{"drugName":"Mavyret","drugSlug":"glecaprevir/pibrentasvir","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1400000000},{"drugName":"Viekira Pak","drugSlug":"ombitasvir/paritaprevir/ritonavir","patentNumber":"","type":"Patent Cliff","expiryDate":"2029-06-01","territory":"US","annualRevenue":1100000000}],"drugCount":6,"phaseCounts":{"marketed":1,"phase_2":3,"phase_1":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Gilead Sciences","Merck & Co.","Bristol-Myers Squibb"],"therapeuticFocus":["Liver Disease","Antivirals"],"financials":{"source":"sec_edgar+yahoo","revenue":102814000,"revenuePeriod":"2017-09-30","revenueHistory":[{"value":102814000,"period":"2017-09-30"},{"value":75927000,"period":"2017-09-30"},{"value":7511000,"period":"2017-06-30"},{"value":8959000,"period":"2017-03-31"},{"value":10417000,"period":"2016-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":106740000,"rdSpendHistory":[{"period":"2025-09-30","value":106740000},{"period":"2024-09-30","value":131476000},{"period":"2023-09-30","value":163524000},{"period":"2022-09-30","value":164522000}],"sgaSpend":43933000,"operatingIncome":-85349000,"operatingIncomeHistory":[{"period":"2025-09-30","value":-85349000},{"period":"2024-09-30","value":-121691000},{"period":"2023-09-30","value":-137207000},{"period":"2022-09-30","value":-123844000}],"netIncome":-81889000,"netIncomeHistory":[{"period":"2025-09-30","value":-81889000},{"period":"2024-09-30","value":-116045000},{"period":"2023-09-30","value":-133816000},{"period":"2022-09-30","value":-121755000}],"eps":-3.84,"epsHistory":[{"period":"2025-09-30","value":-3.84},{"period":"2024-09-30","value":-5.48},{"period":"2023-09-30","value":-6.38},{"period":"2022-09-30","value":-5.91}],"cash":32298000,"cashHistory":[{"period":"2025-09-30","value":32298000},{"period":"2024-09-30","value":37233000},{"period":"2023-09-30","value":85388000},{"period":"2022-09-30","value":43994000}],"totalAssets":280732000,"totalLiabilities":216015000,"totalDebt":57903000,"equity":64717000,"operatingCashflow":-19272000,"operatingCashflowHistory":[{"period":"2025-09-30","value":-19272000},{"period":"2024-09-30","value":-78764000},{"period":"2023-09-30","value":-103154000},{"period":"2022-09-30","value":-84782000}],"capex":-12896000,"capexHistory":[{"period":"2025-09-30","value":-12896000},{"period":"2024-09-30","value":-17948000},{"period":"2023-09-30","value":-9058000},{"period":"2022-09-30","value":-2125000}],"freeCashflow":-32168000,"dividendsPaid":null,"buybacks":null,"employees":120,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":9009000,"ebit":-8831000,"ebitda":-7601000,"period":"2025-12-31","revenue":18615000,"epsBasic":-0.42,"netIncome":-11938000,"rdExpense":20859000,"epsDiluted":-0.42,"grossProfit":null,"operatingIncome":-11253000},{"sga":9702000,"ebit":-16281000,"ebitda":-14997000,"period":"2025-09-30","revenue":15125000,"epsBasic":-0.87,"netIncome":-18700000,"rdExpense":23809000,"epsDiluted":-0.87,"grossProfit":null,"operatingIncome":-18386000},{"sga":9997000,"ebit":-16608000,"ebitda":-15398000,"period":"2025-06-30","revenue":18314000,"epsBasic":-0.85,"netIncome":-18255000,"rdExpense":27210000,"epsDiluted":-0.85,"grossProfit":null,"operatingIncome":-18893000},{"sga":11388000,"ebit":-22235000,"ebitda":-21032000,"period":"2025-03-31","revenue":14926000,"epsBasic":-1.06,"netIncome":-22644000,"rdExpense":28065000,"epsDiluted":-1.06,"grossProfit":null,"operatingIncome":-24527000},{"sga":12846000,"ebit":-20744000,"ebitda":-19855000,"period":"2024-12-31","revenue":16959000,"epsBasic":-1.05,"netIncome":-22290000,"rdExpense":27656000,"epsDiluted":-1.05,"grossProfit":null,"operatingIncome":-23543000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":13.96,"previousClose":14.03,"fiftyTwoWeekHigh":17.15,"fiftyTwoWeekLow":5.04,"fiftyTwoWeekRange":"5.04 - 17.15","fiftyDayAverage":13.66,"twoHundredDayAverage":12.11,"beta":1.01,"enterpriseValue":430274208,"forwardPE":-6.8,"priceToBook":3.2,"priceToSales":5.86,"enterpriseToRevenue":6.22,"enterpriseToEbitda":-7.76,"pegRatio":0,"ebitda":-55430000,"ebitdaMargin":-80.1,"freeCashflow":0,"operatingCashflow":0,"totalDebt":186616992,"debtToEquity":160.1,"currentRatio":3.84,"returnOnAssets":-11.8,"returnOnEquity":-59,"analystRating":"1.2 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":7,"targetMeanPrice":20.14,"targetHighPrice":28,"targetLowPrice":14,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":4.7,"institutionHeldPercent":91.2,"sharesOutstanding":29078380,"floatShares":20213582,"sharesShort":2155192,"shortRatio":18.17,"shortPercentOfFloat":7.4,"epsTrailing":-2.6,"epsForward":-2.06,"revenuePerShare":2.75,"bookValue":4.36,"officers":[{"age":69,"name":"Dr. Jay R. Luly Ph.D.","title":"President, CEO & Director"},{"age":73,"name":"Dr. Yat Sun Or Ph.D.","title":"Chief Scientific Officer"},{"age":51,"name":"Dr. Scott T. Rottinghaus M.D.","title":"Chief Medical Officer"},{"age":56,"name":"Mr. Harry R. Trout III","title":"VP of Finance & Interim Principal Financial Officer"},{"age":40,"name":"Ms. Kathleen S. Capps CPA","title":"Executive Director of Accounting, Controller & Interim Principal Accounting Officer"},{"age":null,"name":"Ms. Jennifer  Viera","title":"Executive Director of Investor Relations & Corporate Communications"},{"age":52,"name":"Mr. Matthew P. Kowalsky J.D.","title":"Chief Legal Officer & Corporate Secretary"},{"age":71,"name":"Mr. Nathaniel S. Gardiner J.D.","title":"Consultant"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.enanta.com","phone":"617 607 0800"}}